194 related articles for article (PubMed ID: 24259495)
1. Soluble form of FGFR2 with S252W partially prevents craniosynostosis of the apert mouse model.
Morita J; Nakamura M; Kobayashi Y; Deng CX; Funato N; Moriyama K
Dev Dyn; 2014 Apr; 243(4):560-7. PubMed ID: 24259495
[TBL] [Abstract][Full Text] [Related]
2. Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.
Suzuki H; Suda N; Shiga M; Kobayashi Y; Nakamura M; Iseki S; Moriyama K
J Cell Physiol; 2012 Sep; 227(9):3267-77. PubMed ID: 22105374
[TBL] [Abstract][Full Text] [Related]
3. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
[TBL] [Abstract][Full Text] [Related]
4. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
[TBL] [Abstract][Full Text] [Related]
5. A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
Tanimoto Y; Yokozeki M; Hiura K; Matsumoto K; Nakanishi H; Matsumoto T; Marie PJ; Moriyama K
J Biol Chem; 2004 Oct; 279(44):45926-34. PubMed ID: 15310757
[TBL] [Abstract][Full Text] [Related]
6. Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.
Wang Y; Sun M; Uhlhorn VL; Zhou X; Peter I; Martinez-Abadias N; Hill CA; Percival CJ; Richtsmeier JT; Huso DL; Jabs EW
BMC Dev Biol; 2010 Feb; 10():22. PubMed ID: 20175913
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse.
Wang Y; Xiao R; Yang F; Karim BO; Iacovelli AJ; Cai J; Lerner CP; Richtsmeier JT; Leszl JM; Hill CA; Yu K; Ornitz DM; Elisseeff J; Huso DL; Jabs EW
Development; 2005 Aug; 132(15):3537-48. PubMed ID: 15975938
[TBL] [Abstract][Full Text] [Related]
8. The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model.
Yang F; Wang Y; Zhang Z; Hsu B; Jabs EW; Elisseeff JH
Bone; 2008 Jul; 43(1):55-63. PubMed ID: 18407821
[TBL] [Abstract][Full Text] [Related]
9. Mandibular dysmorphology due to abnormal embryonic osteogenesis in FGFR2-related craniosynostosis mice.
Motch Perrine SM; Wu M; Stephens NB; Kriti D; van Bakel H; Jabs EW; Richtsmeier JT
Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31064775
[TBL] [Abstract][Full Text] [Related]
10. The Fgfr2(S252W/+) mutation in mice retards mandible formation and reduces bone mass as in human Apert syndrome.
Zhou X; Pu D; Liu R; Li X; Wen X; Zhang L; Chen L; Deng M; Liu L
Am J Med Genet A; 2013 May; 161A(5):983-92. PubMed ID: 23495007
[TBL] [Abstract][Full Text] [Related]
11. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.
Shin HR; Kim BS; Kim HJ; Yoon H; Kim WJ; Choi JY; Ryoo HM
J Cell Physiol; 2022 Apr; 237(4):2155-2168. PubMed ID: 35048384
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis.
Park J; Park OJ; Yoon WJ; Kim HJ; Choi KY; Cho TJ; Ryoo HM
J Cell Biochem; 2012 Feb; 113(2):457-64. PubMed ID: 21928350
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.
Yokota M; Kobayashi Y; Morita J; Suzuki H; Hashimoto Y; Sasaki Y; Akiyoshi K; Moriyama K
PLoS One; 2014; 9(7):e101693. PubMed ID: 25003957
[TBL] [Abstract][Full Text] [Related]
14. Maldevelopment of the submandibular gland in a mouse model of apert syndrome.
Yamaji K; Morita J; Watanabe T; Gunjigake K; Nakatomi M; Shiga M; Ono K; Moriyama K; Kawamoto T
Dev Dyn; 2018 Nov; 247(11):1175-1185. PubMed ID: 30251381
[TBL] [Abstract][Full Text] [Related]
15. Craniofacial divergence by distinct prenatal growth patterns in Fgfr2 mutant mice.
Motch Perrine SM; Cole TM; Martínez-Abadías N; Aldridge K; Jabs EW; Richtsmeier JT
BMC Dev Biol; 2014 Feb; 14():8. PubMed ID: 24580805
[TBL] [Abstract][Full Text] [Related]
16. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
17. Midface and upper airway dysgenesis in FGFR2-related craniosynostosis involves multiple tissue-specific and cell cycle effects.
Holmes G; O'Rourke C; Motch Perrine SM; Lu N; van Bakel H; Richtsmeier JT; Jabs EW
Development; 2018 Oct; 145(19):. PubMed ID: 30228104
[TBL] [Abstract][Full Text] [Related]
18. Negative autoregulation of fibroblast growth factor receptor 2 expression characterizing cranial development in cases of Apert (P253R mutation) and Pfeiffer (C278F mutation) syndromes and suggesting a basis for differences in their cranial phenotypes.
Britto JA; Moore RL; Evans RD; Hayward RD; Jones BM
J Neurosurg; 2001 Oct; 95(4):660-73. PubMed ID: 11596961
[TBL] [Abstract][Full Text] [Related]
19. Novel molecular pathways elicited by mutant FGFR2 may account for brain abnormalities in Apert syndrome.
Yeh E; Fanganiello RD; Sunaga DY; Zhou X; Holmes G; Rocha KM; Alonso N; Matushita H; Wang Y; Jabs EW; Passos-Bueno MR
PLoS One; 2013; 8(4):e60439. PubMed ID: 23593218
[TBL] [Abstract][Full Text] [Related]
20. Facial suture synostosis of newborn Fgfr1(P250R/+) and Fgfr2(S252W/+) mouse models of Pfeiffer and Apert syndromes.
Purushothaman R; Cox TC; Maga AM; Cunningham ML
Birth Defects Res A Clin Mol Teratol; 2011 Jul; 91(7):603-9. PubMed ID: 21538817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
